8-K: NeueHealth Reports Positive Adjusted EBITDA for Second Consecutive Quarter, Reaffirms Full-Year Guidance

NeueHealth announced its second quarter 2024 financial results, highlighting positive adjusted EBITDA for the second consecutive quarter and reaffirming its full-year guidance.

Summary

• NeueHealth reported its financial results for the second quarter ended June 30, 2024, showing a continued focus on its value-driven model.
• The company achieved positive Adjusted EBITDA for the second consecutive quarter in 2024.
• Revenue for the quarter was $225.99 million, compared to $297.98 million in the same quarter of the previous year.
• Net loss for the quarter was $57.698 million, compared to a net loss of $88.627 million in the second quarter of 2023.
• Adjusted EBITDA for the quarter was $3.962 million, compared to $7.797 million in the same quarter of the previous year.
• The company is reaffirming its full-year Adjusted EBITDA guidance of $15 million to $25 million.
• NeueHealth expects to reach the high end of its guidance range for consumers served by year-end.
• The company's revenue for 2024 is expected to be approximately $950 million, with NeueCare revenue at $320 million and NeueSolutions revenue at $640 million.
• The Adjusted Operating Cost Ratio is expected to be between 15% and 16%, excluding corporate costs, and between 19% and 20% including corporate costs.

Sentiment

Score: 5

Explanation: The document presents mixed results with positive Adjusted EBITDA but declining revenue and consumer numbers. The reaffirmation of guidance is positive, but the risks outlined temper overall sentiment.

Positives

• The company achieved positive Adjusted EBITDA for the second consecutive quarter.
• NeueHealth is reaffirming its full-year Adjusted EBITDA guidance.
• The company expects to reach the high end of its guidance range for consumers served by year-end.
• The company is focused on a value-driven model and delivering high-quality care.
• The company has built strong relationships with consumers, providers, and payors.

Negatives

• Revenue decreased to $225.991 million in Q2 2024 from $297.982 million in Q2 2023.
• The company reported a net loss of $57.698 million for the quarter.
• Adjusted EBITDA decreased to $3.962 million in Q2 2024 from $7.797 million in Q2 2023.
• The company's value-based consumers served decreased from 373,000 to 364,000 year-over-year.

Risks

• The company's ability to continue as a going concern is a risk.
• There are risks associated with the company's ability to comply with credit facility terms.
• The company faces risks related to receiving proceeds from the sale of its Medicare Advantage business.
• The company's ability to obtain financing is a risk.
• There are risks associated with winding down the IFP and MA businesses.
• The company faces potential disruptions due to corporate restructuring and headcount reduction.
• The company's ability to manage costs related to changes in business offerings is a risk.
• There are risks related to the adoption of the company's business model.
• The company faces risks related to retaining consumers and expanding enrollment.
• The company's ability to accurately estimate medical expenses is a risk.
• The company faces risks related to reliance on third-party providers.
• The company's ability to manage growth is a risk.
• The company faces risks related to data security incidents.
• The company's ability to adapt to mitigate risks associated with ACO Reach businesses is a risk.

Future Outlook

NeueHealth expects to reach the high end of its guidance range for consumers served by year-end and anticipates continued strong performance this year and beyond. The company is reaffirming its full-year Adjusted EBITDA guidance of $15 million to $25 million and expects revenue of approximately $950 million for 2024.

Management Comments

• Mike Mikan, President and CEO of NeueHealth, stated that the company continued to build momentum in the second quarter, driving solid results in both NeueCare and NeueSolutions segments.
• Mike Mikan believes the company is well-positioned for the future with a strong pipeline in place to drive capital-efficient, sustainable growth in 2024 and beyond.

Industry Context

This announcement comes as the healthcare industry continues to shift towards value-based care models. NeueHealth's focus on aligning the interests of consumers, providers, and payors is in line with this trend. The company's performance is being closely watched by investors as it navigates the complexities of the healthcare market.

Comparison to Industry Standards

• While NeueHealth achieved positive Adjusted EBITDA for the second consecutive quarter, the decrease in revenue and Adjusted EBITDA compared to the same quarter last year is a concern.
• Companies like Oak Street Health and Agilon Health, which also operate in the value-based care space, have shown varying results in recent quarters, with some demonstrating stronger revenue growth.
• The company's Adjusted Operating Cost Ratio guidance of 15-20% is within the range of some industry peers, but the company needs to demonstrate consistent improvement in this metric.
• The decrease in value-based consumers served from 373,000 to 364,000 year-over-year is a negative trend that needs to be addressed.

Stakeholder Impact

• Shareholders will be impacted by the financial results and future outlook.
• Employees may be affected by potential restructuring and headcount reductions.
• Customers will be impacted by the company's ability to deliver high-quality care.
• Providers will be impacted by the company's partnerships and payment models.
• Payors will be impacted by the company's ability to align interests and create a better care experience.

Next Steps

• NeueHealth will discuss the company's results, strategy, and outlook on a conference call with investors at 8:00 a.m. Eastern Time today.
• The company will continue to focus on advancing its value-driven model and delivering high-quality care.

Key Dates

Keywords

Adjusted EBITDA, Healthcare, Financial Results, Value-Based Care, NeueHealth, Revenue, Medicare, Medicaid, ACA Marketplace, Earnings